A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer
A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer
Active, not recruiting · NCT05203445 · Registry updated 2026-05-29Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2026-05-29 | NCT05203445 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Memorial Sloan Kettering Cancer Center | 753 |
| Merck Sharp & Dohme LLC | 650 |
7 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) | Basking Ridge | United States | 131 |
| Memorial Sloan Kettering Bergen (Limited Protocol Activities) | Montvale | United States | 184 |
| Memorial Sloan Kettering Cancer Center (All Protocol Activities) | New York | United States | 230 |
| Memorial Sloan Kettering Monmouth (Limited Protocol Activities) | Middletown | United States | 186 |
| Memorial Sloan Kettering Nassau (Limited Protocol Activities) | Uniondale | United States | 120 |
| Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities) | Commack | United States | 21 |
| Memorial Sloan Kettering Westchester (Limited Protocol Activities) | Harrison | United States | 166 |